NCT04047420View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

March 3, 2021

Study Completion Date

April 7, 2021

Conditions
HIV Infections
Interventions
DRUG

TAF/EVG Insert

TAF/EVG Insert (20/16 mg) administered rectally by study staff

Trial Locations (2)

15213

University of Pittsburgh CRS, Pittsburgh

35294

Alabama CRS, Birmingham

All Listed Sponsors
collaborator

CONRAD

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04047420 - Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally | Biotech Hunter | Biotech Hunter